Menu
Microsoft strongly encourages users to switch to a different browser than Internet Explorer as it no longer meets modern web and security standards. Therefore we cannot guarantee that our site fully works in Internet Explorer. You can use Chrome or Firefox instead.

News

Form 8.3 - The Vanguard Group, Inc.: Mediclinic International plc
Form 8.3 - The Vanguard Group, Inc.: Mediclinic International plc
Form 8.3 - The Vanguard Group, Inc.: Mediclinic International plc
Agilent to Collaborate with Quest Diagnostics to Extend Access to the Agilent Resolution ctDx FIRST Liquid Biopsy Test: https://unsplash.com/photos/MJX7-BAdkt0
Agilent to Collaborate with Quest Diagnostics to Extend Access to the Agilent Resolution ctDx FIRST Liquid Biopsy Test


Agilent Technologies Inc. (NYSE: A) today announced an agreement with Quest Diagnostics (NYSE: DGX), the world’s leading provider of diagnostic information services. The alliance will enable

MD Medical Group Investments Plc: Results of the Extraordinary General Meeting of shareholders
MD Medical Group Investments Plc: Results of the Extraordinary General Meeting of shareholders
MD Medical Group Investments Plc: Results of the Extraordinary General Meeting of shareholders
Savara Announces New Employment Inducement Grant: https://mms.businesswire.com/media/20200730005071/en/747459/5/SavaraLogo.jpg
Savara Announces New Employment Inducement Grant


Savara Inc. (Nasdaq: SVRA), a clinical stage biopharmaceutical company focused on rare respiratory diseases, today announced the grant of inducement awards to two new employees.



On January 17

Form 8.3 - The Vanguard Group, Inc.: Mediclinic International plc
Form 8.3 - The Vanguard Group, Inc.: Mediclinic International plc
Form 8.3 - The Vanguard Group, Inc.: Mediclinic International plc
EQS-Adhoc: BB Biotech AG closes the 2022 fiscal year with a loss
EQS-Adhoc: BB Biotech AG closes the 2022 fiscal year with a loss
EQS-Adhoc: BB Biotech AG closes the 2022 fiscal year with a loss
EQS-News: BB BIOTECH AG: Divergent biotech equity markets mirror value over growth theme in 2022 – Proposed dividend of CHF 2.85
EQS-News: BB BIOTECH AG: Divergent biotech equity markets mirror value over growth theme in 2022 – Proposed dividend of CHF 2.85
EQS-News: BB BIOTECH AG: Divergent biotech equity markets mirror value over growth theme in 2022 – Proposed dividend of CHF 2.85
COLTENE announces key figures for the 2022 financial year
COLTENE announces key figures for the 2022 financial year
COLTENE announces key figures for the 2022 financial year
CenterWell Senior Primary Care Expands Personalized Primary Care to Charlotte, Opening 3 New Centers in 2023: http://s3-eu-west-1.amazonaws.com/sharewise-dev/attachment/file/24514/Humana_logo.png
CenterWell Senior Primary Care Expands Personalized Primary Care to Charlotte, Opening 3 New Centers in 2023


CenterWell Senior Primary Care will open three new senior-focused primary care centers in Charlotte this year, marking the company’s debut in the city and giving seniors access to CenterWell’s

Novocure Announces Organizational Changes to Prepare for Future Growth: https://mms.businesswire.com/media/20191120005453/en/721126/5/novocure_main%405x.jpg
Novocure Announces Organizational Changes to Prepare for Future Growth


Novocure (NASDAQ: NVCR) today announced organizational changes to prepare for future growth, effective Jan. 17.



Pritesh Shah, Novocure’s Chief Commercial Officer, will transition into a new

Form 8.3 - The Vanguard Group, Inc.: Mediclinic International plc
Form 8.3 - The Vanguard Group, Inc.: Mediclinic International plc
Form 8.3 - The Vanguard Group, Inc.: Mediclinic International plc
NanoString Releases Single Cell Spatial Transcriptomics Dataset Highlighting Data Quality of CosMx Spatial Molecular Imager: https://mms.businesswire.com/media/20191104005218/en/753909/5/NSTG-Logo-19-%28002%29.jpg
NanoString Releases Single Cell Spatial Transcriptomics Dataset Highlighting Data Quality of CosMx Spatial Molecular Imager


NanoString Technologies, Inc. (NASDAQ: NSTG), a leading provider of life science tools for discovery and translational research, today announced a public release of new data generated by the CosMx™

Agilent Included in Just Capital’s 2023 List of Most Just Companies: https://unsplash.com/photos/26h317_UMYM
Agilent Included in Just Capital’s 2023 List of Most Just Companies


Agilent Technologies Inc. (NYSE: A) is ranked 35 among the top 100 Most JUST companies, the fifth year the company has been included in the annual list by Just Capital and CNBC. Agilent also earned

LivaNova to Announce Fourth-Quarter and Full-Year 2022 Results: https://mms.businesswire.com/media/20191101005329/en/555341/5/LN-Logo-Main-PANTONE.jpg
LivaNova to Announce Fourth-Quarter and Full-Year 2022 Results


LivaNova PLC (Nasdaq: LIVN), a market-leading medical technology and innovation company, will host a conference call to discuss its fourth-quarter and full-year 2022 results on Wednesday, February

Charles River and Rznomics Announce RNA-based Anticancer Gene Therapy Manufacturing Alliance: https://mms.businesswire.com/media/20191106005189/en/754630/5/charles_river_logo.jpg
Charles River and Rznomics Announce RNA-based Anticancer Gene Therapy Manufacturing Alliance


Charles River Laboratories International, Inc. (NYSE: CRL) and Rznomics Inc., a South Korea-based biopharmaceutical company specialized in the development of RNA-based gene therapeutics, today

Form 8.3 - The Vanguard Group, Inc.: Mediclinic International plc
Form 8.3 - The Vanguard Group, Inc.: Mediclinic International plc
Form 8.3 - The Vanguard Group, Inc.: Mediclinic International plc
QIAGEN Launches EZ2 Connect MDx Platform for Automated Sample Processing in Diagnostic Labs
QIAGEN Launches EZ2 Connect MDx Platform for Automated Sample Processing in Diagnostic Labs


QIAGEN (NYSE: QGEN; Frankfurt Prime Standard: QIA) today announced the launch of EZ2 Connect MDx for use in diagnostic laboratories, making the IVD platform for automated sample processing

QIAGEN bringt EZ2-Connect-MDx-Plattform für automatisierte Probenverarbeitung in Diagnoselaboren auf den Markt
QIAGEN bringt EZ2-Connect-MDx-Plattform für automatisierte Probenverarbeitung in Diagnoselaboren auf den Markt


QIAGEN (NYSE: QGEN; Frankfurt Prime Standard: QIA) hat heute die Markteinführung von EZ2 Connect MDx für den Einsatz in Diagnoselaboren bekannt gegeben. Damit steht die IVD-Plattform für die

Pfizer Expands ‘An Accord for a Healthier World’ Product Offering to Include Full Portfolio for Greater Benefit to 1.2 Billion People in 45 Lower-Income Countrieshttp://www.flickr.com/photos/w0ahitslo/6955091156/sizes/z/in/photostream/: All rights reserved by Queen Beuaroo
Pfizer Expands ‘An Accord for a Healthier World’ Product Offering to Include Full Portfolio for Greater Benefit to 1.2 Billion People in 45 Lower-Income Countries


Pfizer Inc. (NYSE: PFE) today announced that it has significantly expanded its commitment to An Accord for a Healthier World to offer the full portfolio of medicines and vaccines for which it has

QIAGEN N.V. to Release Results for Q4 and Full-Year Results 2022 and Hold Webcast
QIAGEN N.V. to Release Results for Q4 and Full-Year Results 2022 and Hold Webcast


QIAGEN N.V. (NYSE: QGEN) (Frankfurt Stock Exchange: QIA) announced its plans to release results for the fourth quarter and full-year 2022.



Press release date / time: Tuesday, February 7, shortly

EQS-Adhoc: Eckert & Ziegler Exceeds Forecast for the 2022 Financial Year According to Preliminary Figures
EQS-Adhoc: Eckert & Ziegler Exceeds Forecast for the 2022 Financial Year According to Preliminary Figures
EQS-Adhoc: Eckert & Ziegler Exceeds Forecast for the 2022 Financial Year According to Preliminary Figures
Relief Therapeutics Announces IRB Approval of Investigator-Initiated Trial Evaluating RLF-TD011 as an Adjunctive Treatment for Cutaneous T-Cell Lymphom
Relief Therapeutics Announces IRB Approval of Investigator-Initiated Trial Evaluating RLF-TD011 as an Adjunctive Treatment for Cutaneous T-Cell Lymphom
Relief Therapeutics Announces IRB Approval of Investigator-Initiated Trial Evaluating RLF-TD011 as an Adjunctive Treatment for Cutaneous T-Cell Lymphom
Charles River Launches CliniPrime Suite of GMP-Compliant Cellular Products: https://mms.businesswire.com/media/20191106005189/en/754630/5/charles_river_logo.jpg
Charles River Launches CliniPrime Suite of GMP-Compliant Cellular Products


Charles River Laboratories International, Inc. (NYSE:CRL) today announced the launch of their new CliniPrimeTM suite of Good Manufacturing Practice (GMP)-compliant cellular starting materials

Form 8.3 - The Vanguard Group, Inc.: Mediclinic International plc
Form 8.3 - The Vanguard Group, Inc.: Mediclinic International plc
Form 8.3 - The Vanguard Group, Inc.: Mediclinic International plc
ABIONYX Pharma Reports Positive Results from Phase 2a Pilot Clinical Trial Evaluating CER-001 in the Treatment of Septic Patients at High Risk of Developing Acute Kidney Injury: https://mms.businesswire.com/media/20210302005302/en/862456/5/ABIONYX_W.jpg
ABIONYX Pharma Reports Positive Results from Phase 2a Pilot Clinical Trial Evaluating CER-001 in the Treatment of Septic Patients at High Risk of Developing Acute Kidney Injury


ABIONYX Pharma (FR0012616852 – ABNX – PEA PME eligible), a new generation biotech company dedicated to the discovery and development of innovative therapies for patients, today reported that the